The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study

• Autor(a) principal: Silva, José Manuel
• Data de Publicação: 2002
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://revista.spmi.pt/index.php/rpmi/article/view/1852
• topic: Atorvastatina; eficácia; colesterol; HDL; Atorvastatin; eficacy; cholesterol; HDL

The reduction of cholesterol, mainly with statins,achieves one of the most important benefits incardiovascular disease prevention. In Portugal, largestudies with hypolipidaemic drugs are scarce.Therefore we considered it important to conduct astudy to evaluate the efficacy and tolerability ofatorvastatin (10 and 20 mg/day) in Portuguesedyslipidaemic patients. In 16 centres, 208 ambulatorypatients, 18-70 years old, were selected and classifiedaccording to the levels of risk defined by theguidelines of the European Atherosclerosis Societyvalid at the study time. Of the 191 who startedmedication, three abandoned treatment because ofadverse events.There were highly significant differences in lipidvalues between visit V2 (basal) and V3 (one monthafter 10 mg/day of atorvastatin). Total cholesterolwas reduced by 25.2%, LDL cholesterol by 32.2%,and triglycerides by 23.3% (p<0.001). In 17% of thepatients it was necessary to double the dose ofatorvastatin, in order to try to achieve the cholesterolgoals of the respective cardiovascular risk level, andcomparing to V3 levels, total cholesterol decreasedmore 10.0% and the LDL cholesterol more 13.3%.With the 10 mg dose, HDL cholesterol increased by35% (p=0.013) in patients with a basal level under35 mg/dl (n=14), and by 15% (p<0.001) in all patientswith a basal level under 40 mg/dl (n=37).This study, in Portuguese dyslipidaemic patients,confirmed the excellent efficacy and tolerability ofatorvastatin in decreasing LDL cholesterol levelsand in increasing low HDL cholesterol levels.